Strenght Training in Osteoporosis Prevention

NCT06733064 · tracked via the Priya Life Science Poland tracker

Sponsor

Mateusz Karnia

Phase

Not applicable

Started

2024-09-02

Last updated

2024-12-13

Condition(s) studied

Osteopenia or Osteoporosis

Investigational drug(s) / intervention(s)

Supplementation of vitamin D3Placebo

Supplementation of vitamin D3: Supplementation of vitamin d3 at a dose of 4000 iu / day

Placebo: Vegetable oil as a placebo

Study summary

The study involves 120 women over the age of 50.

All participants in the study take part in high-intensity strength training for 10 months.

In addition, half of the participants receive vitamin D3 at a dose of 4,000 IU/day.

The investigators hypothesize that training combined with vitamin D3 supplementation will be more effective in preventing osteoporosis than training alone.

Eligibility

Sex

FEMALE

Min age

50 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * age over 50 * female Exclusion Criteria: * ongoing cancer, * unstabilized cardiovascular disease, * cognitive disorders, * radiological treatment in the last 12 months, * other contraindications to undertaking high-intensity strength training, * diseases affecting the skeleton such as: Paget's disease, type I diabetes mellitus, * taking medications affecting skeletal conditions including: long-term therapy with corticosteroids, thiazides, antiretroviral drugs, * contraindications to taking vitamin D including: hypercalcemia, nephrolithiasis, sarcoidosis, lack of cholecalciferol hydroxylase activity in the liver and kidneys.

Primary outcome measure(s)

Bone Mineral Density — Measured at 3 time points: before the experiment, after 10 months of training, and at 6 months after the end of training and supplementation.
Test to determine bone mineral density by densitometry.

Trial sites (2)

Facility	City	Region	Status
University of Gdańsk, Faculty of Biology	Gdansk	Pomeranian Voivodeship
University of Gdańsk, Faculty of Biology	Gdansk	Poland

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06733064 on ClinicalTrials.gov ↗ ← All trials in Poland